<DOC>
	<DOC>NCT01346592</DOC>
	<brief_summary>This Study Aims to Evaluate the Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to &lt; 72 Months of Age.</brief_summary>
	<brief_title>Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to &lt; 72 Months of Age</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1.Children 6 months to 72 months of age. Children 1. Who had been hospitalized at the time of enrollment 2. Who had any serious reaction or hypersensitivity to any vaccine component, eggs, or chicken protein 3. Who had known impairment of the immune function 4. Who had fever interfering with normal daily activities at the time of enrollment 5. Who had received licensed vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in the study 6. Concomitant participation in another clinical study 7. Who had surgery planned during the study period that in the investigator's opinion would have interfered with the study visits schedule.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>72 Months</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Adjuvanted Trivalent Subunit Influenza Vaccine</keyword>
	<keyword>vaccine</keyword>
	<keyword>influenza</keyword>
	<keyword>adjuvant</keyword>
	<keyword>MF-59</keyword>
	<keyword>pediatric</keyword>
</DOC>